UBS downgraded RxSight (RXST) to Neutral from Buy with a price target of $16, down from $45. The firm cites the company’s lower near-term sales growth and longer path to profitability for the downgrade. It sees limited visibility into the timing of easing macroeconomic pressures that have been limiting overall premium intra-ocular lens adoption. RxSight’s Q1 sales miss and 2025 guidance cut reduced visibility into its underlying growth momentum, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Market Challenges and Revised Growth Projections Lead to Hold Rating
- RxSight’s Strategic Growth and Resilience Justify Buy Recommendation
- RxSight price target lowered to $17 from $22 at Wells Fargo
- RxSight downgraded to Underweight from Overweight at JPMorgan
- Stocks plummet after Trump tariffs, JPMorgan warns of recession: Morning Buzz